As JCV was present in 45.8% of nonnephropathy controls and 8.75% of CKD cases regardless of APOL1 renal risk genotype status, authors postulated a robust CKD protective effect by JCV (OR: 0.15; 95% CI: 0.06–0.42). The gene discussed is APOL1; the disease is chronic kidney disease.